Bronchodilator response to adrenergic β2-agonists: Relationship to symptoms in an adult community

Respiratory Medicine

Volumn 101, Issue 6, 2007, Pages 1183-1190

  Lehmann, Sverre ^a,b   Bakke, Per Sigvald ^a,b   Eide, Geir Egil ^a,b   Gulsvik, Amund ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Albuterol Salbutamol; Epidemiology (Pulmonary); Pulmonary function test

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; GLUCOCORTICOID; SALBUTAMOL; THEOPHYLLINE;

ADULT; AGED; ARTICLE; BRONCHODILATATION; CLIMBING; COLD EXPOSURE; COMMUNITY CARE; CONFIDENCE INTERVAL; CONTROLLED STUDY; COUGHING; DISEASE ASSOCIATION; DRUG RESPONSE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALER; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; NORWAY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; SEX DIFFERENCE; SYMPTOM; WHEEZING;

ADRENERGIC BETA-AGONISTS; AGE FACTORS; AGED; ALBUTEROL; BODY MASS INDEX; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; COUGH; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; RESPIRATION DISORDERS; RESPIRATORY SOUNDS; VITAL CAPACITY;

EID: 34247570452     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.11.007     Document Type: Article

References (35)

1. BTS. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59 (Suppl I): 1-232.
2. Celli B.R., and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004) 932-946
3. GINA. Global Strategy for Asthma Management and Prevention. NIH Publication No 02-3659 Issued January, 1995 (updated 2002). The GINA reports are available on 〈www.ginasthma.org〉.
4. Malmstrom K., Rodriguez-Gomez G., Guerra J., et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Ann Intern Med 130 (1999) 487-495
5. Haahtela T., Jarvinen M., Kava T., et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 331 (1994) 700-705
6. Bateman E.D., Boushey H.A., Bousquet J., et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 170 (2004) 836-844
7. Pellegrino R., Viegi G., Brusasco V., et al. Interpretative strategies for lung function tests. Eur Respir J 26 (2005) 948-968
8. Appleton S.L., Adams R.J., Wilson D.H., Taylor A.W., and Ruffin R.E. Spirometric criteria for asthma: adding further evidence to the debate. J Allergy Clin Immunol 116 (2005) 976-982
9. Nygard O., Vollset S.E., Refsum H., et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland homocysteine study. Jama 274 (1995) 1526-1533
10. Bjartveit K., Foss O.P., Gjervig T., and Lund-Larsen P.G. The cardiovascular disease study in Norwegian counties. Background and organization. Acta Med Scand Suppl 634 (1979) 1-70
11. Burney P.G., Laitinen L.A., Perdrizet S., et al. Validity and repeatability of the IUATLD (1984) Bronchial Symptoms Questionnaire: an international comparison. Eur Respir J 2 (1989) 940-945
12. Burney P.G., Chinn S., Britton J.R., Tattersfield A.E., and Papacosta A.O. What symptoms predict the bronchial response to histamine? Evaluation in a community survey of the bronchial symptoms questionnaire (1984) of the international union against tuberculosis and lung disease. Int J Epidemiol 18 (1989) 165-173
13. Gulsvik A., Bakke P., Humerfelt S., Omenaas E., and Baste V. Measurements of respiratory symptoms and sample size to detect a given difference between treatment groups in obstructive lung disease. Eur Respir Rev 1 (1991) 436-443
14. Brogger J.C., Bakke P.S., and Gulsvik A. Comparison of respiratory symptoms questionnaires. Int J Tuber Lung Dis 4 (2000) 83-90
15. Bakke P., Gulsvik A., Eide G.E., and Hanoa R. Smoking habits and lifetime occupational exposure to gases or dusts including asbestos and quartz in a Norwegian community. Scand J Work Environ Health 16 (1990) 195-202
16. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-36.
17. ATS. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991: 1202-18.
18. Lehmann S., Vollset S.E., Nygaard H.A., and Gulsvik A. Factors determining performance of bronchodilator reversibility tests in middle-aged and elderly. Respir. Med. 98 (2004) 1071-1079
19. Gulsvik A., Tosteson T., Bakke P., Humerfelt S., Weiss S.T., and Speizer F.E. Expiratory and inspiratory forced vital capacity and one-second forced volume in asymptomatic never-smokers in Norway. Clin Physiol 21 (2001) 648-660
20. SPSS for Windows 2004. Rel. 13.0.1. Chicago: SPSS Inc; 2004.
21. Johannessen A., Lehmann S., Omenaas E.R., Eide G.E., Bakke P.S., and Gulsvik A. Post-bronchodilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med 173 (2006) 1316-1325
22. Burney P.G., Luczynska C., Chinn S., and Jarvis D. The European Community Respiratory Health Survey. Eur Respir J 7 (1994) 954-960
23. The European Community Respiratory Health Survey II. Eur Respir J 2002; 20: 1071-9.
24. Pekkanen J., Sunyer J., Anto J.M., and Burney P. On behalf of the European Community Respiratory Health Study (ECRHS). Operational definitions of asthma in studies on its aetiology. Eur Respir J 26 (2005) 28-35
25. Bai J., Peat J.K., Berry G., Marks G.B., and Woolcock A.J. Questionnaire items that predict asthma and other respiratory conditions in adults. Chest 114 (1998) 1343-1348
26. Anthonisen N.R., Lindgren P.G., Tashkin D.P., Kanner R.E., Scanlon P.D., and Connett J.E. Bronchodilator response in the lung health study over 11 yrs. Eur Respir J 26 (2005) 45-51
27. Douma W.R., de Gooijer A., Rijcken B., et al. Lack of correlation between bronchoconstrictor response and bronchodilator response in a population-based study. Eur Respir J 10 (1997) 2772-2777
28. Devereux G., Hendrick D., and Stenton S. Perception of respiratory symptoms after methacholine-induced bronchoconstriction in a general population. Eur Respir J 12 (1998) 1089-1093
29. Di Marco F., Verga M., Reggente M., et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respir Med 100 (2006) 1767-1774
30. King G.G., Brown N.J., Diba C., et al. The effects of body weight on airway calibre. Eur Respir J 25 (2005) 896-901
31. Belman M.J., Botnick W.C., and Shin J.W. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153 (1996) 967-975
32. Jeffery P.K. Differences and similarities between chronic obstructive pulmonary disease and asthma. Clin Exp Allergy 29 Suppl 2 (1999) 14-26
33. Jeffery P.K. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 164 (2001) S28-S38
34. Kang H., Koh Y.Y., Yoo Y., Yu J., Kim D.K., and Kim C.K. Maximal airway response to methacholine in cough-variant asthma: comparison with classic asthma and its relationship to peak expiratory flow variability. Chest 128 (2005) 3881-3887
35. Mariotta S., Sposato B., Ricci A., Bruno P., Aquilini M., and Mannino F. Reversibility test in the early stages of bronchial asthma. J Asthma 42 (2005) 487-491